The traditional Japanese formula keishibukuryogan inhibits the production of inflammatory cytokines by dermal endothelial cells.
Keishibukuryogan (KBG) is one of the traditional herbal formulations widely administered to patients with blood stagnation for improving blood circulation; currently, it is the most frequently prescribed medicine in Japan. KBG has been reported to improve conjunctional microcirculation. The aim of this study was to evaluate the role of KBG and paeoniflorin, a bioactive compound of KBG, in inhibiting the production of inflammatory cytokines using human dermal microvessel endothelial cells (HDMECs). The authors observed that lipopolysaccharide (LPS; 1 μg/mL) stimulated the secretion of proinflammatory cytokines in HDMECs. KBG treatment (10 mg/mL) significantly suppressed the mRNA levels of migration inhibitory factor (MIF), interleukin (IL)-6, IL-8, and tumor necrosis factor (TNF)-α in LPS-stimulated cultured HDMECs. Similarly, paeoniflorin significantly suppressed the mRNA levels of these cytokines in LPS-stimulated cultured HDMECs. ELISA showed that KBG and paeoniflorin suppressed the production of MIF, IL-6, IL-8, and TNF-α in LPS-stimulated HDMECs. Moreover, KBG and paeoniflorin decreased the expression of cyclooxygenase-2 and inducible nitric oxide synthase (iNOS) in these cells. These results suggest that KBG may be useful for improving microvascular inflammation in patients with skin diseases.
Department of Dermatology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Sugitani, Toyama 930-0194, Japan.
Yoko
Y
Yoshihisa
Megumi
M
Furuichi
Mati
M
Ur Rehman
Chieko
C
Ueda
Teruhiko
T
Makino
Tadamichi
T
Shimizu
D002460:Cell Line; D002478:Cells, Cultured; D051546:Cyclooxygenase 2 / Q000096:biosynthesis; D016207:Cytokines / Q000096:biosynthesis*; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D042783:Endothelial Cells / Q000187:drug effects*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D006801:Humans; D007249:Inflammation / Q000188:drug therapy*; D008070:Lipopolysaccharides / Q000494:pharmacology; D008833:Microcirculation; D052247:Nitric Oxide Synthase Type II / Q000096:biosynthesis; D012333:RNA, Messenger / Q000378:metabolism; D012867:Skin / Q000187:drug effects*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D016207:Cytokines; D004365:Drugs, Chinese Herbal; D008070:Lipopolysaccharides; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; C054593:keishibukuryogan; D052247:Nitric Oxide Synthase Type II; D051546:Cyclooxygenase 2
Diabetes Res Clin Pract. 2008 Apr;80(1):40-7
18242756
Biol Pharm Bull. 2008 Jun;31(6):1141-4
18520044
Evid Based Complement Alternat Med. 2006 Sep;3(3):359-64
16951720
Int J Dermatol. 1995 Dec;34(12):846-50
8647662
J Ethnopharmacol. 2002 Nov;83(1-2):153-9
12413723
Toxicol In Vitro. 2009 Sep;23(6):1014-9
19540912
Neurol Med Chir (Tokyo). 2010 Jan;50(1):1-5; discussion 5-6
20098017
J Pharmacobiodyn. 1984 Jul;7(7):427-35
6491862
Am J Obstet Gynecol. 1986 Nov;155(5):1134-9
3777061
Arthritis Rheum. 2004 Sep;50(9):3023-34
15457472
Jpn J Pharmacol. 1986 Jun;41(2):263-5
3747270
Eur J Pharmacol. 1992 Feb 11;211(2):177-82
1612108
Yakugaku Zasshi. 1982 Sep;102(9):881-6
7153865
J Biochem Mol Biol. 2007 Mar 31;40(2):189-95
17394768
Phytomedicine. 2004 Feb;11(2-3):188-95
15070171
J Pharmacobiodyn. 1982 Nov;5(11):921-9
6131955
J Ethnopharmacol. 2007 Mar 21;110(2):311-7
17123761
Br J Pharmacol. 2003 Jul;139(6):1146-52
12871833
Evid Based Complement Alternat Med. 2008 Dec;5(4):463-74
18955217
Phytomedicine. 2003;10(6-7):459-66
13678228
Mediators Inflamm. 2004 Aug;13(4):293-5
15545061
Microvasc Res. 2002 Nov;64(3):384-97
12453433
Inflamm Res. 2008 Apr;57(4):189-98
18363035
Jpn J Pharmacol. 1995 Nov;69(3):281-4
8699638
Phytother Res. 2002 Sep;16(6):524-8
12237808
Br J Dermatol. 1996 Jan;134(1):180-1
8745912
J Interferon Cytokine Res. 2000 Sep;20(9):751-62
11032394
Int Immunopharmacol. 2005 Sep;5(10):1560-73
16023608
Planta Med. 1997 Aug;63(4):323-5
9270377
Br J Pharmacol. 2005 Oct;146(4):604-11
16086036
J Am Acad Dermatol. 1999 Aug;41(2 Pt 1):207-8
10426890
Pharmacol Biochem Behav. 1993 Jul;45(3):719-23
8332629